Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Structure-based drug discovery for Dopamine D2 Receptor Selective Ligands

Award Number: R43MH115875
ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2017
PERIOD OF PERFORMANCE END DATE: 06/30/2018

Group Awards By:

View Award Description

Structure-based drug discovery for Dopamine D2 Receptor Selective Ligands - Summary The neurotransmitter dopamine (DA) controls many central nervous system functions through three major pathways in the brain, the tuberoinfundibular, the nigrostriatal and the mesocorticolimic (mesocortical and mesolimbic). Each is associated with different processes, and dysfunction can lead to varying diseases and disorders. There are five known DA receptors, D2 (D2R) is one of the most abundant DA receptors in the brain, and is thus an important pharmacological target for many central nervous system diseases. Most of the clinically efficacious antipsychotics used for the treatment of schizophrenia and Parkinson's disease, which are associated with the mesocorticolimbic and nigrostriatal pathways, are D2R agonists or antagonists. In addition, several drugs abused by humans (ie. psychostimulants such as cocaine and methamphetamine) affect DA neurotransmission in the mesolimbic pathway, due to their effects on reward-related behaviours. Therefore D2R is also a focus for the discovery of pharmacological treatments for substance abuse of a certain class of drugs and addiction disorders for which there are none currently available. The goal of this proposal is to clone, express and purify active-state stabilized D2R in quantities amenable to pursue initial crystallization trials. To obtain active-state stabilized protein crystals, D2R will be bound with agonist and complexed with purified G-protein and/or a stabilizing nanobody. This will enable our longer term goal of x-ray crystallographic structure determination and the discovery of D2R selective small molecule ligands for the treatment of substance abuse disorders. This proposal is in response to the Funding Opportunity Announcement PA-16- 302: PHS 2016-02 Omnibus Solicitation of the NIH, CDC, FDA, and ACF for Small Business Innovation Research Grant Appplications (Parent SBIR [R43/R44]).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2017	CONFOMETRX	840 CHIMALUS DR	PALO ALTO	CA	94306	SANTA CLARA	USA	Mental Health Research Grants	000	1	8/28/2018	NEW	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $193,685 )
2017	2017	CONFOMETRX	840 CHIMALUS DR	PALO ALTO	CA	94306	SANTA CLARA	USA	Mental Health Research Grants	000	1	7/1/2017	NEW	$193,685
														Subtotal = $193,685

Grand Total All Awards = $193,685

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Structure-based drug discovery for Dopamine D2 Receptor Selective Ligands

Award Number: R43MH115875

ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2017

PERIOD OF PERFORMANCE END DATE: 06/30/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer